Beryl Drugs Ltd

Beryl Drugs Annual Report

Beryl Drugs Ltd has submitted its 33rd Annual Report for the financial year 2025-26, scheduled for its upcoming Annual General Meeting.

Beryl Drugs Annual General Meeting

Beryl Drugs Ltd has announced the closure of its register of members from September 23 to September 29, 2026, for its 33rd Annual General Meeting.

Beryl Drugs Board Meeting Outcome

Beryl Drugs Limited approved items for its 33rd Annual General Meeting and a proposal to increase material related party transaction limits.

Beryl Drugs Board Meeting Date

Beryl Drugs Ltd has scheduled a Board Meeting for September 2, 2026, to approve the Board report and matters related to its 33rd Annual General Meeting.

Beryl Drugs Promoter Buying

Sudhir Sethi, a promoter of Beryl Drugs Limited, acquired 3,000 equity shares via market transactions. This acquisition increases the promoter's total stake from 10.08% to 10.14%.

Beryl Drugs Q1 FY27 Results: Net Profit ₹0.2 Cr, Down 66.7% QoQ

Beryl Drugs Ltd reported revenue from operations of ₹7.3 Cr (+52.1% YoY) and net profit of ₹0.2 Cr for Q1 FY27.

Key figure

Net profit ₹0.2 Cr

Beryl Drugs Board Meeting Outcome

Beryl Drugs Ltd's board meeting on August 11, 2026, approved the unaudited financial results for the quarter ended June 30, 2026.

Beryl Drugs Board Meeting Date

Beryl Drugs Ltd's Board of Directors will meet on August 11, 2026, to approve unaudited financial results for the quarter ended June 30, 2026.

Beryl Drugs Adverse Business Impact

Beryl Drugs Ltd reported the temporary unavailability of its corporate website due to technical issues. The company stated there is no impact on business operations.